Options traders are hedging into CIB's August earnings. Short sellers, meanwhile, have largely exited.
The put-call ratio hit 0.6479 on July 20. That is the highest in three weeks. More significantly, it sits 3.65 standard deviations above the 20-day mean of 0.40. That is a sharp defensive shift in a name that has traded with consistently bullish options sentiment all month.
Grupo Cibest reports on August 3. The PCR spike reads as pre-earnings hedging. That context matters. The 52-week PCR low is 0.21 and the high is 5.85 — so 0.65 is not an extreme level in absolute terms. But the sudden jump from a tight 0.39–0.45 band over the prior two weeks is notable.
Goldman Sachs raised its price target on CIB to $81 from $71 on July 16, maintaining a Neutral rating. That target is now almost exactly in line with the current price of $80.82. B of A Securities upgraded the stock to Neutral in June. Analyst momentum has been consistently upward since January.
The PCR move, then, is not a bearish consensus call. It reads more like protection being bought against an event risk in a stock that has already re-rated.
The short position has collapsed. Shares short stood at roughly 868,000 on July 8. By July 17 that had fallen to 468,000 — a 45% drop in nine days. The ORTEX short score sits at 26.9, down from 28.7 on July 8, consistent with reduced shorting pressure.
The borrow market is extremely loose. Availability stands at a maximum reading, with 18 million shares available to lend against fewer than 500,000 currently borrowed. Cost to borrow is 0.46% — low, and broadly stable over the past month.
Short selling is simply not a dominant force in this name right now.
BlackRock added 2.5 million shares as of June 30, bringing its stake to 8.7% of shares outstanding. Two Sigma added 1.2 million shares in Q1. These are modest flows in the context of a stock with 948 million shares outstanding, but they show consistent institutional accumulation.
The PE sits at 8.2x and price-to-book at 1.67x. Both multiples have expanded over the past 30 days alongside the price move.
Data summary
See the live data behind this article on ORTEX.
Open CIB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
